Protection of rhesus macaques against inhalational anthrax with a Bacillus anthracis capsule conjugate vaccine.
Vaccine
; 34(34): 4012-6, 2016 07 25.
Article
en En
| MEDLINE
| ID: mdl-27329184
ABSTRACT
The efficacy of currently licensed anthrax vaccines is largely attributable to a single Bacillus anthracis immunogen, protective antigen. To broaden protection against possible strains resistant to protective antigen-based vaccines, we previously developed a vaccine in which the anthrax polyglutamic acid capsule was covalently conjugated to the outer membrane protein complex of Neisseria meningitidis serotype B and demonstrated that two doses of 2.5µg of this vaccine conferred partial protection of rhesus macaques against inhalational anthrax . Here, we demonstrate complete protection of rhesus macaques against inhalational anthrax with a higher 50µg dose of the same capsule conjugate vaccine. These results indicate that B. anthracis capsule is a highly effective vaccine component that should be considered for incorporation in future generation anthrax vaccines.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Ácido Poliglutámico
/
Infecciones del Sistema Respiratorio
/
Cápsulas Bacterianas
/
Vacunas contra el Carbunco
/
Carbunco
Idioma:
En
Revista:
Vaccine
Año:
2016
Tipo del documento:
Article